Sorbonne Université, Science Norms Democracy, UMR 8011, Paris, France.
Programa de Bioética, Facultad Latinoamericana de Ciencias Sociales (FLACSO), Buenos Aires, Argentina.
J Alzheimers Dis. 2022;90(3):989-992. doi: 10.3233/JAD-215647.
Given the unknown therapeutic value of targeting Alzheimer's disease pathology and the discovery of robust risk factors for dementia, non-pharmacological risk reduction (RR) is increasingly offered as an alternative to targeting Alzheimer's disease pathology. While RR will surely be a useful tool to make public health gains, we propose solutions to three possible issues with over-reliance on multi-domain interventions to achieve RR: limited individual impact, an exclusive focus on later life, and overlooking social determinants of dementia. We argue in favor of a broader debate within the research community and greater society about how different therapeutic avenues should be explored.
鉴于针对阿尔茨海默病病理学的治疗价值未知，以及发现了痴呆症的强大风险因素，非药物风险降低 (RR) 越来越多地被作为针对阿尔茨海默病病理学的替代方法提供。虽然 RR 肯定会成为取得公共卫生收益的有用工具，但我们提出了解决过度依赖多领域干预措施来实现 RR 可能出现的三个问题的方案：个体影响有限、仅关注晚年生活以及忽视痴呆症的社会决定因素。我们主张在研究界和更广泛的社会内进行更广泛的辩论，探讨应该如何探索不同的治疗途径。
